Summit Global Investments Invests $541,000 in Krystal Biotech, Inc. (NASDAQ:KRYS)

Summit Global Investments purchased a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the 4th quarter, HoldingsChannel reports. The fund purchased 3,453 shares of the company’s stock, valued at approximately $541,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Wilmington Savings Fund Society FSB acquired a new position in shares of Krystal Biotech during the third quarter valued at about $40,000. Avanza Fonder AB acquired a new position in Krystal Biotech during the 4th quarter valued at about $119,000. KBC Group NV boosted its stake in Krystal Biotech by 46.3% during the 4th quarter. KBC Group NV now owns 939 shares of the company’s stock valued at $147,000 after purchasing an additional 297 shares during the last quarter. Blue Trust Inc. increased its holdings in Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock worth $159,000 after purchasing an additional 433 shares in the last quarter. Finally, US Bancorp DE raised its stake in shares of Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after purchasing an additional 82 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Chardan Capital lifted their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research report on Thursday, February 20th. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. HC Wainwright restated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Finally, Citigroup increased their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Krystal Biotech has a consensus rating of “Buy” and an average price target of $220.00.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $194.44 on Tuesday. Krystal Biotech, Inc. has a 52 week low of $141.72 and a 52 week high of $219.34. The firm’s 50-day simple moving average is $167.55 and its two-hundred day simple moving average is $173.62. The firm has a market cap of $5.60 billion, a price-to-earnings ratio of 65.03 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same quarter in the prior year, the business earned $0.30 earnings per share. Krystal Biotech’s revenue for the quarter was up 116.4% on a year-over-year basis. Analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).